AI in Drug Development

Targeted Synthesis and Development of Neotype Antiviral Agents with a Radical-Mediated Deoxyphosphoamination Strategy

by
Targeted Synthesis and Development of Neotype Antiviral Agents with a Radical-Mediated Deoxyphosphoamination Strategy

Follow us | Discover more exciting content Today, we share a research article published in September 2025 by the Animal Immunology and Metabolism Innovation Team and the Pathobiology Research Center for Livestock Diseases at the Lanzhou Institute of Veterinary Research, Chinese Academy of Agricultural Sciences, in the Journal of the American Chemical Society titled “Targeted … Read more

After the Chip: U.S. Biotech Sanctions Begin, China’s Innovative Drug Breakthrough Battle Commences

by
After the Chip: U.S. Biotech Sanctions Begin, China's Innovative Drug Breakthrough Battle Commences

Recently, the U.S. restrictions on the Chinese biotechnology sector have shifted from “expectation” to “actual action”. On September 12, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) placed 23 Chinese entities on the “Entity List”, including three biotechnology companies: Beijing Tianyi Huiyuan Biotechnology Co., Ltd., Beijing Qinke Biotechnology Co., Ltd., and … Read more

New Frontiers in Medicinal Chemistry: In-Depth Analysis of DAC Technology

by
New Frontiers in Medicinal Chemistry: In-Depth Analysis of DAC Technology

Following antibody-drug conjugates (ADCs), a new drug form known as “Degrader-Antibody Conjugate” (DAC) is gaining attention in the field of oncology and other diseases due to its unique “targeted protein degradation” mechanism. 1 What is DAC?DAC, short for Degrader-Antibody Conjugate, is an innovative drug conjugation technology. It cleverly combines the targeting specificity of monoclonal antibodies … Read more

Over $140 Billion! The ADC Market Explosion: A Golden Opportunity for Chinese Innovative Drugs and Potential Billion-Dollar Candidates

by
Over $140 Billion! The ADC Market Explosion: A Golden Opportunity for Chinese Innovative Drugs and Potential Billion-Dollar Candidates

Medical Road Society:Inheriting and Developing Traditional Chinese Medicine Source: Overseas Website, Author: Compiled by Medical Road Society Copyright belongs to the original author. If there are any violations or infringements, please contact us for removal! 👆 Follow for more innovative drug news Hello everyone! I am an observer focused on innovative drugs. Today, let’s talk … Read more

ADC: Where It Comes From and Where It Is Going?

by
ADC: Where It Comes From and Where It Is Going?

ADC, or antibody-drug conjugates, is a term that everyone is likely familiar with. The design concept of ADC originated from Paul Ehrlich’s idea of “magic bullets,” aimed at achieving precise targeted therapy while minimizing damage to normal tissues. As of now, there are 15 ADC drugs approved for market worldwide, with over 400 ADC candidates … Read more

Global Analysis of ADC Drugs | HER2 Target

by
Global Analysis of ADC Drugs | HER2 Target

Global Analysis of ADC Drugs: Popular, Emerging Targets and Star Drugs The human epidermal growth factor receptor2 (HER2) is one of the most extensively studied and fruitful targets in ADC drugs.HER2 belongs to the ERBB receptor tyrosine kinase family and is overexpressed or amplified in various epithelial-derived tumors, including breast cancer, gastric cancer, and non-small … Read more

Microfluidic Chip Technology: Exploration and Practice in the Modernization of Traditional Chinese Medicine

by
Microfluidic Chip Technology: Exploration and Practice in the Modernization of Traditional Chinese Medicine

General Secretary Xi Jinping pointed out: “Traditional Chinese medicine (TCM) is a treasure of ancient Chinese science and a key to unlocking the treasure house of Chinese civilization.” As an outstanding representative of traditional medicine, TCM is a gem of Chinese civilization. We must follow the development laws of TCM, inherit its essence, and innovate … Read more

The Evolution of Antibody-Drug Conjugates (ADCs)

by
The Evolution of Antibody-Drug Conjugates (ADCs)

–01– Introduction Antibody-drug conjugates (ADCs) are known as “magic bullets”, precisely targeting tumor cells through antibodies to deliver cytotoxic drugs, combining the precision of targeted therapy with the potent lethality of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field in anti-tumor … Read more

General Principles for Multi-Regional Clinical Trials Planning and Design

by
General Principles for Multi-Regional Clinical Trials Planning and Design

As drug development becomes increasingly globalized, Multi-Regional Clinical Trials (MRCT) have become an important tool for supporting the simultaneous approval of drugs worldwide. The ICH E17 guidelines, released in November 2017 by the International Council for Harmonisation (ICH), provide a systematic framework for the planning and design of MRCTs. This article aims to provide a … Read more

Understanding Antibody-Drug Conjugates (ADCs) and Their Core Components

by
Understanding Antibody-Drug Conjugates (ADCs) and Their Core Components

Click the blue text above to follow us Editor’s Note: With their unique mechanisms of action and powerful efficacy, Antibody-Drug Conjugates (ADCs) have become indispensable treatment methods for various solid tumors and hematological cancers, such as breast cancer. The core component that determines the efficacy of ADCs is undoubtedly the payload. Different payloads exhibit significant … Read more